Preclinical study identifies possible therapeutic target for cardiovascular risk factors that avoid the common problem of an increased risk of fatty liver disease.
Otman covers neurosciences, cardiology and dermatology for Michigan Medicine. A television news producer turned health care communicator, Otman specializes in storytelling, media relations and social media surrounding clinical advances, new research and compelling patient stories.
New findings give reason to pay attention to metabolic dysfunction well before middle age.
Researchers report the ability to improve safety and efficacy using a CRISPR-Cas9 variant known as miCas9.
Basic science research explores the effects of impaired glycine metabolism in nonalcoholic fatty liver disease and how to potentially use glycine-based treatment to help people with NAFLD.